{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T05:16:10Z","timestamp":1735708570900,"version":"3.32.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Key R&D Planning Project of Jiangxi Science and Technology Commission, China","award":["20203BBGL73126"],"award-info":[{"award-number":["20203BBGL73126"]}]},{"name":"Science and Technology Program of Ganzhou","award":["GZ2023ZSF452"],"award-info":[{"award-number":["GZ2023ZSF452"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-80639-0","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T18:39:55Z","timestamp":1735583995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Application of rapid genotyping of Warfarin individualized pharmacogenetic variants in Warfarin therapy"],"prefix":"10.1038","volume":"14","author":[{"given":"Defa","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangfang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengpeng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minyang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Die","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baodian","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangli","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyu","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"issue":"4","key":"80639_CR1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1055\/s-0042-1742363","volume":"122","author":"LA Ritchie","year":"2022","unstructured":"Ritchie, L. A., Penson, P. E. & Lane, D. A. Warfarin-Is self-care the best care? Thromb. Haemost 122(4), 471\u2013474 (2022).","journal-title":"Thromb. Haemost"},{"issue":"6","key":"80639_CR2","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1002\/cpt.2754","volume":"112","author":"SA Morris","year":"2022","unstructured":"Morris, S. A. et al. Cost effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines: a systematic review. Clin. Pharmacol. Ther. 112(6), 1318\u20131328 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"doi-asserted-by":"crossref","unstructured":"Biswas, M. et al. Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin: Results of a 5 years audit. Indian Heart J 70 Suppl 3 (Suppl 3), S13-S19. (2018).","key":"80639_CR3","DOI":"10.1016\/j.ihj.2018.02.005"},{"issue":"2","key":"80639_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cgh.2023.09.012","volume":"22","author":"N Yoshida","year":"2024","unstructured":"Yoshida, N. et al. An analysis of delayed bleeding in cases of colorectal endoscopic submucosal dissection due to types of direct oral anticoagulants in Japan. Clin. Gastroenterol. Hepatol. 22(2), 271\u2013282 (2024). e3.","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"12","key":"80639_CR5","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00228-010-0863-9","volume":"66","author":"Q Gu","year":"2010","unstructured":"Gu, Q. et al. VKORC1-1639G\u2009>\u2009A, CYP2C9, EPHX1691A\u2009>\u2009G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China. Eur. J. Clin. Pharmacol. 66(12), 1217\u20131227 (2010).","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"80639_CR6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/cpt.668","volume":"102","author":"JA Johnson","year":"2017","unstructured":"Johnson, J. A. et al. Clinical pharmacogenetics implementation Consortium (CPIC) Guideline for Pharmacogenetics-guided warfarin dosing: 2017 update. Clin. Pharmacol. Ther. 102(3), 397\u2013404 (2017).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9","key":"80639_CR7","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1161\/STROKEAHA.122.042055","volume":"54","author":"E Almallouhi","year":"2023","unstructured":"Almallouhi, E. et al. Ameliorating racial disparities in vascular risk factor management with Aggressive Medical Management in the SAMMPRIS Trial. Stroke 54(9), 2235\u20132240 (2023).","journal-title":"Stroke"},{"issue":"2","key":"80639_CR8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/cpt.288","volume":"99","author":"AD Roses","year":"2016","unstructured":"Roses, A. D. Polyallelic structural variants can provide accurate, highly informative genetic markers focused on diagnosis and therapeutic targets: Accuracy vs. Precision. Clin. Pharmacol. Ther. 99(2), 169\u2013171 (2016).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"80639_CR9","first-page":"418","volume":"72","author":"MB Ghafoor","year":"2022","unstructured":"Ghafoor, M. B. et al. VKORC1 gene polymorphism (-1639G\u2009>\u2009A) in warfarin therapy patients of Pakistani population. J. Pak Med. Assoc. 72(3), 418\u2013423 (2022).","journal-title":"J. Pak Med. Assoc."},{"doi-asserted-by":"crossref","unstructured":"Altawil, Y. & Youssef, L. A. Frequencies of VKORC1-1639G\u2009>\u2009A and rs397509427 in Patients on Warfarin and Healthy Syrian Subjects. Cardiovasc Ther 2023, 8898922. (2023).","key":"80639_CR10","DOI":"10.1155\/2023\/8898922"},{"issue":"5","key":"80639_CR11","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41397-020-0157-2","volume":"20","author":"E Panchenko","year":"2020","unstructured":"Panchenko, E. et al. CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients. Pharmacogenomics J. 20(5), 687\u2013694 (2020).","journal-title":"Pharmacogenomics J."},{"issue":"1","key":"80639_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.thromres.2011.11.043","volume":"130","author":"R Liang","year":"2012","unstructured":"Liang, R. et al. Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis. Thromb. Res. 130(1), 38\u201344 (2012).","journal-title":"Thromb. Res."},{"key":"80639_CR13","doi-asserted-by":"publisher","first-page":"797278","DOI":"10.3389\/fphar.2021.797278","volume":"12","author":"S Nie","year":"2021","unstructured":"Nie, S. et al. Effect of CYP4F2 polymorphisms on Ticagrelor Pharmacokinetics in healthy Chinese volunteers. Front. Pharmacol. 12, 797278 (2021).","journal-title":"Front. Pharmacol."},{"issue":"3","key":"80639_CR14","doi-asserted-by":"publisher","first-page":"826","DOI":"10.7150\/ijms.51546","volume":"18","author":"LN Al-Eitan","year":"2021","unstructured":"Al-Eitan, L. N. et al. Influence of CYP4F2, ApoE, and CYP2A6 gene polymorphisms on the variability of warfarin dosage requirements and susceptibility to cardiovascular disease in Jordan. Int. J. Med. Sci. 18(3), 826\u2013834 (2021).","journal-title":"Int. J. Med. Sci."},{"issue":"5","key":"80639_CR15","first-page":"2558","volume":"7","author":"C Chen","year":"2014","unstructured":"Chen, C. et al. High resolution melting method to detect single nucleotide polymorphism of VKORC1 and CYP2C9. Int. J. Clin. Exp. Pathol. 7(5), 2558\u20132564 (2014).","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"1","key":"80639_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2217\/pgs.09.138","volume":"11","author":"J Zhu","year":"2010","unstructured":"Zhu, J. et al. ARMS test for diagnosis of CYP2C9 and VKORC1 mutation in patients with pulmonary embolism in Han Chinese. Pharmacogenomics 11(1), 113\u2013119 (2010).","journal-title":"Pharmacogenomics"},{"issue":"3","key":"80639_CR17","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/FPC.0b013e328326e0c7","volume":"19","author":"SW Huang","year":"2009","unstructured":"Huang, S. W. et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics 19 (3), 226\u2013234 (2009).","journal-title":"Pharmacogenet Genomics"},{"issue":"6","key":"80639_CR18","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1309\/1E34UAPR06PJ6HML","volume":"129","author":"CR King","year":"2008","unstructured":"King, C. R. et al. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. Am. J. Clin. Pathol. 129(6), 876\u2013883 (2008).","journal-title":"Am. J. Clin. Pathol."},{"doi-asserted-by":"crossref","unstructured":"Holail, J., Mobarak, R., Al-Ghamdi, B., Aljada, A. & Fakhoury, H. Association of VKORC1 and CYP2C9 single-nucleotide polymorphisms with warfarin dose adjustment in Saudi patients. Drug Metab. Pers. Ther. (2022).","key":"80639_CR19","DOI":"10.1515\/dmdi-2022-0108"},{"issue":"1","key":"80639_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/cpt.1598","volume":"107","author":"F Rodrigues-Soares","year":"2020","unstructured":"Rodrigues-Soares, F. et al. I.-A. N. o.; Pharmacogenomics, Genomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 among Latin americans. Clin. Pharmacol. Ther. 107(1), 257\u2013268 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"80639_CR21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12872-018-0837-x","volume":"18","author":"J Li","year":"2018","unstructured":"Li, J. et al. Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation. BMC Cardiovasc. Disord 18(1), 96 (2018).","journal-title":"BMC Cardiovasc. Disord"},{"issue":"2","key":"80639_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2217\/17410541.4.2.157","volume":"4","author":"N Limdi","year":"2007","unstructured":"Limdi, N. et al. Influence of CYP2C9 genotype on warfarin dose among African American and European americans. Per Med. 4(2), 157\u2013169 (2007).","journal-title":"Per Med."},{"issue":"1","key":"80639_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1039\/C5LC01094B","volume":"16","author":"B Zhuang","year":"2016","unstructured":"Zhuang, B. et al. A fully integrated and automated microsystem for rapid pharmacogenetic typing of multiple warfarin-related single-nucleotide polymorphisms. Lab. Chip 16(1), 86\u201395 (2016).","journal-title":"Lab. Chip"},{"issue":"6","key":"80639_CR24","doi-asserted-by":"publisher","first-page":"424","DOI":"10.5152\/AnatolJCardiol.2022.1376","volume":"26","author":"Z Li","year":"2022","unstructured":"Li, Z. et al. Low-dose NOACs Versus Standard-Dose NOACs or warfarin on efficacy and safety in Asian patients with NVAF: a Meta-analysis. Anatol. J. Cardiol. 26(6), 424\u2013433 (2022).","journal-title":"Anatol. J. Cardiol."},{"issue":"1\u20132","key":"80639_CR25","first-page":"1","volume":"25","author":"N Kaur","year":"2021","unstructured":"Kaur, N. et al. Genetic and nongenetic determinants of variable warfarin dose requirements: a Report from North India. Public. Health Genomics 25(1\u20132), 1\u20139 (2021).","journal-title":"Public. Health Genomics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80639-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80639-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80639-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T09:10:16Z","timestamp":1735636216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80639-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["80639"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-80639-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"18 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This project was approved by the Ethical Committee on Scientific Research of First Affiliated Hospital of Gannan Medical University (No. LLSC-2023042401).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All human blood samples were obtained with written informed consent from all subjects.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"31639"}}